中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.019 seconds)

    CDIM BINDING PROTEINS AND USES THEREOF
    2.
    发明申请
    CDIM BINDING PROTEINS AND USES THEREOF 审中-公开
    CDIM结合蛋白及其用途

    公开(公告)号：WO2013120012A3

    公开(公告)日：2013-11-07

    申请号：PCT/US2013025430

    申请日：2013-02-08

    Applicant: IGM BIOSCIENCES INC ,  TENG NELSON N H ,  BHAT NEELIRNA M ,  BIEBER MARCIA M ,  KEYT BRUCE A

    Inventor： TENG NELSON N H ,  BHAT NEELIRNA M ,  BIEBER MARCIA M ,  KEYT BRUCE A

    IPC: C07K16/28 ,  C07K16/30

    CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/734 ,  C07K2317/92

    Abstract: The present disclosure relates to Cell Death Inducing Molecule ("CDIM") binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.

    Abstract translation: 本公开涉及细胞死亡诱导分子（“CDIM”）结合蛋白及其药物组合物。 特别地，本公开提供了CDIM结合蛋白，其用于选择性地消除和杀死B细胞，包括肿瘤B细胞以及不表达CDIM样抗原的B细胞来源的赘生性细胞。 此外，本公开内容涵盖编码所公开的抗原结合蛋白的多核苷酸，以及用于生产它们的表达系统。 此外，本公开还包括通过施用CDIM结合蛋白治疗患有B细胞增殖和介导的疾病的患者的方法以及用于鉴定结合CDIM的蛋白的诊断测定。 本公开进一步考虑了用于鉴定可以用CDIM结合蛋白治疗的患者群体的诊断测定。

    VARIANTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR HAVING ANTAGONISTIC PROPERTIES
    5.
    发明申请
    VARIANTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR HAVING ANTAGONISTIC PROPERTIES 审中-公开
    具有拮抗特性的血管内皮细胞生长因子的变异

    公开(公告)号：WO9816551A2

    公开(公告)日：1998-04-23

    申请号：PCT/US9719471

    申请日：1997-10-10

    Applicant: GENENTECH INC ,  KEYT BRUCE A ,  NGUYEN FRANCIS HUNG ,  FERRARA NAPOLEONE

    Inventor： KEYT BRUCE A ,  NGUYEN FRANCIS HUNG ,  FERRARA NAPOLEONE

    IPC: C12N15/09 ,  A61K38/00 ,  A61P9/10 ,  A61P17/06 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/52 ,  C12N5/10 ,  C12N15/19 ,  C07K14/00

    CPC classification number: A61K38/1866 ,  C07K14/52

    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) antagonist molecules comprising variant VEGF polypeptides which are capable of binding to and occuyping cell surface VEGF receptors without inducing a VEGF response, thereby antagonizing the biological activity of the native VEGF protein. Specifically, the variant VEGF polypeptides of the present invention comprise modifications of at least one cysteine residue in the native VEGF sequence, thereby inhibiting the ability of the variant polypeptide to dimerize through the formation of disulfide bonds. The present invention is further directed to methods for preparing such variant VEGF antagonists and to methods, compositions and assays utilizing such variants for producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from the native VEGF protein.

    Abstract translation: 本发明涉及制备包含变体VEGF多肽的血管内皮生长因子（VEGF）拮抗剂分子，其能够结合并且不影响细胞表面VEGF受体而不诱导VEGF应答，从而拮抗天然VEGF蛋白的生物学活性。 具体地，本发明的变体VEGF多肽包含天然VEGF序列中至少一个半胱氨酸残基的修饰，从而通过形成二硫键来抑制变体多肽二聚的能力。 本发明还涉及制备这种变体VEGF拮抗剂的方法以及利用这些变体产生具有不同于天然VEGF蛋白的治疗和药理学性质的药物活性物质的方法，组合物和测定法。

    CDIM BINDING PROTEINS AND USES THEREOF
    6.
    发明申请
    CDIM BINDING PROTEINS AND USES THEREOF 审中-公开
    CDIM结合蛋白及其用途

    公开(公告)号：WO2013120012A2

    公开(公告)日：2013-08-15

    申请号：PCT/US2013/025430

    申请日：2013-02-08

    Applicant: IGM BIOSCIENCES INC. ,  TENG, Nelson, N.H. ,  BHAT, Neelirna, M. ,  BIEBER, Marcia, M. ,  KEYT, Bruce, A.

    Inventor： TENG, Nelson, N.H. ,  BHAT, Neelirna, M. ,  BIEBER, Marcia, M. ,  KEYT, Bruce, A.

    IPC: C07K16/28

    CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/734 ,  C07K2317/92

    Abstract: The present disclosure relates to Cell Death Inducing Molecule ("CDIM") binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.

    Abstract translation: 本公开涉及细胞死亡诱导分子（“CDIM”）结合蛋白及其药物组合物。 特别地，本公开提供了可用于选择性消耗和杀死B细胞的CDIM结合蛋白，所述B细胞包括肿瘤性B细胞以及不是表达CDIM样抗原的B细胞来源的肿瘤细胞。 此外，本公开包括编码所公开的抗原结合蛋白的多核苷酸，以及用于制备其的表达系统。 此外，本公开包括通过施用CDIM结合蛋白以及用于鉴定结合CDIM的蛋白质的诊断测定法来治疗患有B细胞增殖和介导的疾病的患者的方法。 本公开进一步设想用于鉴定可用CDIM结合蛋白治疗的患者群体的诊断测定。

Patent Agency Ranking